38th Meeting of National Working Group on Indonesian Medicinal Plant

ISBN : 978-602-96839-1-2
978-602-96839-3-6

Proceedings

International Conference On Medicinal Plants

The Future of Medicinal Plants:
From Plant to Medicine

Surabaya, 21-22 July 2010

Organized by

POKJANAS

DAAD
Deutscher Akademischer Austauschdienst
German Academic Exchange Service

Sharing Expertise with Others
50

ISBN : 978-602-96839-1-2
ISBN of Volume 2 : 978-602-96839-3-6

PROCEEDING OF INTERNATIONAL CONFERENCE ON MEDICINAL PLANTS

in occasion of

the 38th Meeting of National Working Group on Indonesian Medicinal Plant

21-21 July 2010
Surabaya, Indonesia

Editor :

Elisabeth C. Widjajakusuma

Organizing Committee

FACULTY OF PHARMACY
WIDYA MANDALA CATHOLIC UNIVERSITY

in collaboration with
National Working Group on Indonesian Medicinal Plants
and German Academic Exchange Service

PREFACE

The International Conference on Medicinal Plants in occasion of the 38th Meeting of National Working Group on Medicinal Plant was held on the campus of Widya Mandala Catholic University in Surabaya during 21-22 July 2010. Over 300 participants had many fruitful discussions and exchanges that contributed to the success of conference. The present volume Proceedings (Volume 2) includes the papers presented at the conference and continues where Volume 1 leaves off.

The 192 abstracts that were presented on two days formed the heart of the conference and provided ample opportunity for discussion. Of the total number of presented abstracts, 63 of these are included in the Volume 1 and 58 in this proceedings volume. Both of the Conference Proceedings cover all aspects on key issues related to medicinal uses of plants, their active ingredients and pharmacological effects, production and cultivation of medicinal plants.

We appreciate the contribution of the participants and on behalf of all the conference participants we would like to express our sincere thanks to plenary speakers, Dr. Mona Tawab, Prof. Henk van Wilgenburg, Prof. Tohru Mitsunaga, Prof. De-An Guo, dr. Arijanto Jonosewojo, SpPD FINASIM, Dr. Bambang Prayogo, Mr. Jimmy Sidharta, Ir. Dwi Mayasari Tjahjono, S.Pd, Dipl. Cidesco,Dipl. Cibtac , and everybody who helped to make conference success and especially to our sponsors

National Working Group on Indonesian Medicinal Plants (POKJANAS TOI)
German Academic Exchange Service (DAAD)
PT. Landson
PT. Gujati 59
PT. Pasifik Sarana Cantik
PT. Herbal Plus
PT. Kaliroto

May you all be richly rewarded by the LORD.

All in all, the Conference was very successful. The plenary lectures and the progress and special reports bridged the gap between the different fields of the development of medicinal plants, making it possible for non-experts in a given area to gain insight into new areas. Also, included among the speakers were several young scientists, namely, students, who brought new perspectives to their fields. I hope this proceedings will promote the interdisciplinary exchange of knowledge and ideas in medicinal plant and related industries.

Dr.phil.nat. Elisabeth Catherina Widjajakusuma
Conference Chairman

ISBN : 978-602-96839-3-6(vol 2)

CONTENT

ISBN : 978-602-96839-3-6(vol 2)

ISBN : 978-602-96839-3-6(vol 2)

ISBN : 978-602-96839-3-6(vol 2)

ISBN : 978-602-96839-3-6(vol 2)

ISBN : 978-602-96839-3-6(vol 2)

ISBN : 978-602-96839-3-6(vol 2)

ISBN : 978-602-96839-3-6(vol 2)

THE DEVELOPMENT OF TABLET FORMULATION OF *ARTOCARPUS CHAMPEDEN* STEMBARK EXTRACT AS ANTIMALARIAL DRUG

Achmad Fuad Hafid[1*], Andang Miatmoko[2], Agriana Rosmalina Hidayati[1], Lidya Tumewu[1], Achmad Radjaram[2], Aty Widyawaruyanti[1]

[1]Phytochemistry and Pharmacognosy Department, [2]
Pharmaceutics Department, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
*Corresponding author, Jalan Dharmawangsa Dalam, Surabaya, East Java, (031)7530806, e-mail: achmadfuad@yahoo.com)

Abstract: Parasite resistance to antimalarial drug, chloroquine and sulfadoxin-pirimetamin, still become a major problem in malaria control worldwide, therefore, the effort in developing a new and different target of antimalarial drug become a high priority. Our preliminary test revealed that extract from *A. champeden* exhibiedt potent antimalarial activities againts *P. falciparum in vitro* and *P. berghei in vivo.* Several isolated compounds from this plant exhibited antimalarial activity. One of the isolated compound identified as heteroflavon C, a prenylated flavone, have a higher antimalarial activity than chloroquine. Therefore, it is potential to be developed as antimalarial drug. The research was conducted to develop tablet formulation of ethanol extract of *A. champeden* stembark (EEAC). The formula that composed : EEAC 150 mg, lactose 140 mg, cab-o-sil 5%, amilum 46 mg, avicel PH 101 7%, primogel 5%, and Mg stearat 1% was the selected formula. The tablet hardness of the formula has span between 9.0-12.27 kP and the average is 10.78 kP, the disintegration time of formula 12 minutes 47 seconds. A standard 4-days test on *P. berghei* infected mice was used to evaluated *in vivo* antimalarial activity of the tablet. This research revealed that EEAC tablet has antimalarial activity against parasite *P. berghei in vivo.* Oral administration of EEAC tablet at a dose of 10 mg/kg body weight multiple dose (twice a day) inhibited the parasite growth better than 100 mg/kg body weight single dose (once a day). Antimalarial activity of tablet in multiple dose per oral showed inhibition of parasite growth of 73.88 %, while at single dose per oral showed inhibition of parasite growth of 83.32%.

Keywords *: A.champeden,* tablet formulation, *P. berghei, in vivo* antimalarial activity

INTRODUCTION

Parasite resistance to antimalarial drug, chloroquine and sulfadoxin-pirimetamin, still become a major problem in malaria control worldwide, therefore, the effort in developing a new and different target of antimalarial drug become a high priority. *Artocarpus champeden* (family Moraceae) known as "cempedak", is widely distributed in Indonesia and has been traditionally used in malarial remedies (Heyne, 1987). Previous study reported that prenylated stilbene from *Artocarpus integer* (syn *A. champeden*) exhibited antimalarial activities againts *P falciparum* (Boonlaksiri et al., 2000). Our preliminary test revealed that extract from *A. champeden* exhibited potent antimalarial activities againts *P. falciparum in vitro* and *P. berghei in vivo.* Several isolated compounds from this plant exhibited antimalarial activity (Hidayati, 2003; Utomo, 2003; Ernawati, 2005). One of the isolated compound identified as heteroflavon C, a prenylated flavone, have a higher antimalarial activity than chloroquine (Widyawaruyanti et al., 2007[a]). Standarized ethanol extract of *A.champeden* stembark (EEAC) also exhibited potent antimalarial activities againts *P. falciparum in vitro* and *P. berghei in vivo.* Therefore, it is potential to develop EEAC as antimalarial phytopharmaceutical product. As phytopharmaceutical product , that requires consistency in the efficacy, safety, and effectivity (Widyawaruyanti *et al.*, 2007[b]; Widyawaruyanti, 2008).

The research was conducted to develop tablet formulation of EEAC and to evaluate the effectivity as antimalarial drug.

MATERIALS AND METHODS

Materials

The stembark of *A. champeden* were collected from Mugirejo, Samarinda, East Kalimantan, Indonesia on October 2009.

The tablet excipients used were lactose monohydrate, amilum manihot as filler, colloidal silicon dioxide (Cab-o-Sil) as absorbent and glidant, microcrystalline cellulose (Avicel PH 101) and sodium starch glycolate (Primogel) as disintegrant and magnesium stearate as lubricant.

Preparation of extract

10 kg powdered cempedak stembark was macerated with ethanol solvent 80% during 2 hour with warm-up at temperature 40°C. Then it was filtered. The residue dried and re-macerated with the same solvent for three times. Extract collected and evaporated to obtain concentrate EEAC.

Preparation of EEAC tablets

The tablet formulation containing EEAC were prepared according to the formula given in table 1. Tablets were prepared by wet granulation method. Extract was dissolved in ethanol for homogenization then mixed with lactose monohydrate, amilum manihot, Cab-O-Sil, Avicel PH101 and Primogel (internal phase disintegrant). The moist mass was granulated by passing them through a 12 mesh sieve (2,100 μm) then dried at 40°C. After the drying process, the granules obtained were resieved through a 18 mesh sieve (1,400 μm). Then the granules were mixed with sodium starch glycolate (external phase disintegrant) and Mg stearate.

The granules were compressed into tablets (final weight 430 mg) by means of spherical punch (1.0 mm in diameter) using laboratory single-punch tablet pump for 1 second with loads of 2 tons. The tablets were evaluated for physical characteristics including tablet hardness, weight uniformity, friability and disintegration time. Then were determined for its antimalarial activity.

Table 1. Formula of EEAC Tablets

Component	Quantity
Internal addition	
EEAC	150 mg
Lactose monohydrate	140 mg
Cab-o-Sil	5%
Amilum manihot	46 mg
Avicel PH 101	7%
Primogel	5%
External addition	
Primogel	5%
Mg stearat	1%
Tablet weight	430 mg

Tablet organolpetic and weight uniformity

Tablets were evaluated for their physical appearance visually and also for its higroscopicity. For tablet weight uniformity, 20 tablets were weighed individually by using O'Hauss miligram balance

Crushing Strength and Friability Tests

The load (kP) required to diametrically break each tablet was determined at room temperature using Erweka Hardness tester. Ten tablets were used for its determination. The friability of the tablets were evaluated for 20 tablets using Erweka Friability Tester which operated at 50 rotation per minute for 10 minutes.

Disintegration Test

The disintegration time of tablets were determined in distilled water at 37±0.5^{0}C using an Erweka disintegration testing apparatus.

Evaluation of Tablet Properties

a. Physical appeareance, tablets were evaluated for their physical appearance visually and also for higroscopicity.
b. Tablet hardness, it was determined for 10 tablets using Erweka Hardness Tester.
c. Tablet weight uniformity, 20 tablets were weighed individually by using O'Hauss miligram balance. The result should fulfill the requirements.

In vivo antimalarial test

Antimalarial activity of EEAC tablet was determined by modification of the "4-day Supressived Test" originally described by Peters (1980).

For each experiment, mice were randomly assigned to a given treatment group (five mice in each group). The day of infection is termed D0, and succeeding day of infection are termed D1, D2, etc. EEAC tablet was suspended in CMC-Na (0.5%) and was given to mice once a day at dose 100 mg/kg body weight (as single dose) and twice a day 10 mg/kg body weight (as multiple dose). While untreated group received CMC-Na (0.5%) solution. Thin blood smear were made from the tail blood everyday. The level of parasitemia in mice, as seen in Giemsa-stained smears, were assessed.

RESULT AND DISCUSSION

Result of Formulation Study of EEAC Optimation formula of EEAC tablet

EEAC tablets have been successfully prepared and evaluated. The tablets were evaluated for uniformity of weight, hardness, friability, and disintegration time. The results of physical appearance of EEAC tablet prepared using wet granulation method shows good physical appearance and relatively non higroscopic. The result indicate that the tablets fullfill the requirement (398,3 – 462,9 mg mg) which have range of tablet weight between 424,8 - 435,0 mg. A good degree of uniformity of weight was achieved for all of tablet prepared. The percent deviation did not exceed 5%, indicating excellent uniformity of weight in the tablet formulations prepared (Table 2).

The tablet exhibited good mechanical properties with regard to both hardness and friability (Tables 3 and 4). The crushing strength test results interval value of tablets hardness between 9.0 - 12.27 kP with an average is 10,78 kP. In the friability studies, weight loss values of the tablet was less than 1%.

The result of disintegration time of EEAC tablet shows the time required for all tablets to break up into small particle is 11 minutes 56 seconds. This is less than traditional medicine requisite which stated time of disintegration should be less than 20 minutes.

Table 2.Result of evaluation uniformity of weight of EEAC tablet

No	weight (mg)	No.	weight (mg)
1	432.2	11	432.5
	427.8	12	433.3
3	430.6	13	435.0
4	426.7	14	428.7
5	431.3	15	433.0
6	424.8	16	431.7
7	430.9	17	432.1
8	428.7	18	432.5
9	431.9	19	427.4
10	430.7	20	430.0
Interval = 424.8 – 435.0 mg Requisite = 398.3 – 462.9 mg (7.5%)			
Average = 430.6 mg			
Standart deviation = 2.54%			

Table 3. Result of evaluation hardness of EEAC tablet

No	Hardness (kP)
1	9.02
2	10.32
3	10.51
4	10.89
5	11.83
6	10.51
7	9.06
8	12.65
9	12.27
10	10.76
Interval = 9.0 - 12.27 kP	
Average = 10.78 kP	
Standart deviation = 1.21 %	

Table 4. Result of evaluation friability of EEAC tablet

Weight before test	8,624.2 mg
Weight after test	8,607.4 mg
Percentage of weight loss	0.19%

In vivo antimalarial test

Antimalaria activity test result from various therapy models of EEAC tablets showed at fig 1. The result showed that EEAC tablet given as single dose and multiple dose can inhibit the growth of parasite, compare with the untreated group. Three day after the treatment ended, the inhibition percentage for EEAC tablet as single dose was 83.32% and multiple dose was 73,88%.

The dosage of EEAC tablet given twice a day is five times than given once a day. It concluded that multiple dose (twice a day, 10 mg/kg body weight) more effective than single dose (once a day, 10 mg/kg body weight).



Fig 1. Graphic of parasitemia percentage *P. berghei* infected mice

CONCLUSION

The formula of EEAC tablet that composed : EEAC 150 mg, lactose 140 mg, cab-o-sil 5%, amilum 46 mg, avicel PH 101 7%, primogel 5%, and Mg stearat 1% was active as antimalarial drug. Oral administration of EEAC tablet at dose of 10 mg/kg body weight multiple dose (twice a day) more potential than 100 mg/kg body weight single dose (once a day).

ACKNOWLEGEMENT

This study received financial support from DIKTI RUSNAS No. 171/SP2H/PP/DP2M/V/2009.

REFERENCES

Boonlaksiri C., Oonanant W., Kongsaeree P., Kittakoop P., Tanticharoen M., Thebtaranonth Y., 2000, An antimalarial stilbene from Artocarpus integer. J Phytochem, **54**, 415-417.

Ernawati S., Widyawaruyanti A., Zaini N. C., 2005, Efek Antimalaria Fraksi Metanol (F5M) Kulit Batang Artocarpus champeden Spreng Terhadap Pertumbuhan Plasmodium berghei in vivo, Skripsi, Fakultas Farmasi Unair, Surabaya.

Heyne K., 1987, Tumbuhan Berguna Indonesia II, Badan Penelitian dan Pengembangan Kehutanan, Departemen Kehutanan, Jakarta : Yayasan Sarana Wana Jaya.

Hidayati A.R., Widyawaruyanti A., Ekasari W., 2003, Uji aktivitas antimalaria fraksi kloroform kulit batang cempedak (Artocarpus champeden) terhadap Plasmodium berghei in-vivo, Skripsi, Fakultas Farmasi Unair, Surabaya.

Utomo D. W., Widyawaruyanti A., Ekasari W., 2003, Aktivitas antimalaria ekstrak methanol kulit batang cempedak (Artocarpus champeden Spreng.) terhadap Plasmodium berghei in-vivo, Skripsi, Fakultas Farmasi Unair, Surabaya.

Widyawaruyanti A., Hafid A. F., W. Ekasari, D. Sjafruddin, N.C. Zaini, 2007[b], Ekstrak terstandart kulit batang cempedak (Artocarpus champeden Spreng.) sebagai bahan baku obat fitofarmaka antimalaria potensial, Laporan Penelitian Tahun I DP2M/Hibah Bersaing/2007-2008, Lembaga Penelitian Unair.

Widyawaruyanti A., Subehan, Kalauni S. K., Awale S., Nindatu M., Zaini N. C., Sjafruddin D., Asih P. B. S., Tezuka Y., Kadota S., 2007[a], New prenylated flavones from Artocarpus champeden and their antimalarial activity in vitro, *J.Nat Med.*, **61**, 410-4

AUTHOR INDEX

PLANT NAMES INDEX (Volume 1 and 2)







Sponsored by

Landson
Improving Quality of Life

GUJATI 59
Sehatnya Terbukti..!
Brand Jamu Indonesia

Mustika Pindiyati
Aromatherapy
Traditional and Natural Product
The first and leading of
Traditional & Natural Indonesia
Professional SPA Products
since 1988

HerbaPlus
Berkhasiat - Lebih Aman - Lebih Baik